Disruptions in NUP62 can indirectly affect the pharmacodynamics of certain antiviral therapies and cancer treatments like gefitinib, afatinib, and erlotinib. Although not directly targeted, NUP62's involvement in nuclear-cytoplasmic transport and cellular signaling processes can influence the effectiveness and dosage of these drugs by altering intracellular dynamics.